UCSF Helen Diller Family Comprehensive Cancer Center | Strategic Alliance Partners

BCMA-directed CAR T-cell therapy is drastically changing the multiple myeloma treatment landscape.

The addition of immunotherapy to the triple-negative breast cancer (TNBC) armamentarium has led to a paradigm shift and sparked an abundance of research with immuno-oncology (IO) drugs in new combinations and settings, explained Hope S. Rugo, MD.

CAR T-cell therapy is poised to have a significant impact on the treatment of patients with relapsed/refractory multiple myeloma, says Nina Shah, MD.